Oncologic photodynamic therapy photosensitizers: a clinical review

RR Allison, CH Sibata - Photodiagnosis and photodynamic therapy, 2010 - Elsevier
A myriad of naturally occurring and synthetic structures are capable of transferring the
energy of light. Few, however, allow for this energy transfer to enable a type II photochemical …

Photosensitizers in clinical PDT

RR Allison, GH Downie, R Cuenca, XH Hu… - Photodiagnosis and …, 2004 - Elsevier
Photosensitizers in photodynamic therapy allow for the transfer and translation of light
energy into a type II chemical reaction. In clinical practice, photosensitizers arise from three …

Anticancer activity of metal complexes: involvement of redox processes

U Jungwirth, CR Kowol, BK Keppler, CG Hartinger… - 2011 - liebertpub.com
Cells require tight regulation of the intracellular redox balance and consequently of reactive
oxygen species for proper redox signaling and maintenance of metal (eg, of iron and …

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase …

CA Meyers, JA Smith, A Bezjak, MP Mehta… - Journal of clinical …, 2004 - ascopubs.org
Purpose To report the neurocognitive findings in a phase III randomized trial evaluating
survival and neurologic and neurocognitive function in patients with brain metastases from …

Whole-brain radiotherapy in the management of brain metastasis

D Khuntia, P Brown, J Li, MP Mehta - Journal of Clinical Oncology, 2006 - ascopubs.org
Brain metastases are an important cause of morbidity and mortality, afflicting nearly 170,000
Americans annually. The prognosis for these patients is poor, with median survival times …

Management of brain metastases

R Soffietti, R Rudā, R Mutani - Journal of neurology, 2002 - Springer
Brain metastases occur in 20–40% of patients with cancer and their frequency has
increased over time. Lung, breast and skin (melanoma) are the commonest sources of brain …

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

MP Mehta, P Rodrigus, CHJ Terhaard… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: This phase III randomized trial evaluated survival as well as neurologic and
neurocognitive function in patients with brain metastases from solid tumors receiving whole …

[HTML][HTML] Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases

R Gencheva, Q Cheng, ESJ Arner - Free Radical Biology and Medicine, 2022 - Elsevier
Human thioredoxin reductase (TrxR) is a selenoprotein with a central role in cellular redox
homeostasis, utilizing a highly reactive and solvent-exposed selenocysteine (Sec) residue in …

Current management of brain metastases, with a focus on systemic options

CJ Langer, MP Mehta - Journal of clinical oncology, 2005 - ascopubs.org
Brain metastases are an important sequelae of many types of cancer, most commonly lung
cancer. Current treatment options include whole-brain radiation therapy (WBRT), surgical …

Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy?

M van Vulpen, HB Kal, MJB Taphoorn… - Oncology …, 2002 - spandidos-publications.com
The brain requires a stable internal environment, which is established by the integrity of the
blood-brain barrier (BBB). The efficacy of chemotherapeutics in the treatment of brain …